NZ630260A - Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same - Google Patents
Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the sameInfo
- Publication number
- NZ630260A NZ630260A NZ630260A NZ63026013A NZ630260A NZ 630260 A NZ630260 A NZ 630260A NZ 630260 A NZ630260 A NZ 630260A NZ 63026013 A NZ63026013 A NZ 63026013A NZ 630260 A NZ630260 A NZ 630260A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disorder
- dihydrate
- salt
- producing
- syndrome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636920P | 2012-04-23 | 2012-04-23 | |
| US201361791378P | 2013-03-15 | 2013-03-15 | |
| PCT/JP2013/062681 WO2013162046A1 (en) | 2012-04-23 | 2013-04-23 | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630260A true NZ630260A (en) | 2015-09-25 |
Family
ID=48428584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630260A NZ630260A (en) | 2012-04-23 | 2013-04-23 | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US9499525B2 (OSRAM) |
| EP (1) | EP2841431B2 (OSRAM) |
| JP (1) | JP5952917B2 (OSRAM) |
| KR (1) | KR102160395B1 (OSRAM) |
| CN (1) | CN104254530B (OSRAM) |
| AR (1) | AR090774A1 (OSRAM) |
| AU (1) | AU2013253372B2 (OSRAM) |
| BR (1) | BR112014026424B1 (OSRAM) |
| CA (1) | CA2870000C (OSRAM) |
| CO (1) | CO7111315A2 (OSRAM) |
| CY (1) | CY1119103T1 (OSRAM) |
| DK (1) | DK2841431T4 (OSRAM) |
| EA (1) | EA026541B1 (OSRAM) |
| ES (1) | ES2617881T5 (OSRAM) |
| FI (1) | FI2841431T4 (OSRAM) |
| HR (1) | HRP20170242T4 (OSRAM) |
| HU (1) | HUE031997T2 (OSRAM) |
| IL (1) | IL235044B (OSRAM) |
| IN (1) | IN2014DN08867A (OSRAM) |
| JO (1) | JO3325B1 (OSRAM) |
| LT (1) | LT2841431T (OSRAM) |
| ME (1) | ME02619B (OSRAM) |
| MX (1) | MX361723B (OSRAM) |
| MY (1) | MY170220A (OSRAM) |
| NZ (1) | NZ630260A (OSRAM) |
| PH (1) | PH12014502324A1 (OSRAM) |
| PL (1) | PL2841431T5 (OSRAM) |
| PT (1) | PT2841431T (OSRAM) |
| RS (1) | RS55742B2 (OSRAM) |
| SG (1) | SG11201406790VA (OSRAM) |
| SI (1) | SI2841431T2 (OSRAM) |
| SM (2) | SMT201700130T1 (OSRAM) |
| TW (1) | TWI562991B (OSRAM) |
| UA (1) | UA117456C2 (OSRAM) |
| WO (1) | WO2013162046A1 (OSRAM) |
| ZA (1) | ZA201407477B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| MX2016013889A (es) * | 2014-04-22 | 2017-03-09 | Otsuka Pharma Co Ltd | Medicamento. |
| CN104447723A (zh) * | 2014-11-28 | 2015-03-25 | 瑞阳制药有限公司 | 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法 |
| CN104829603A (zh) * | 2015-05-19 | 2015-08-12 | 杭州新博思生物医药有限公司 | A晶型依匹唑派盐酸盐及其制备方法 |
| CN106883223B (zh) * | 2015-12-16 | 2021-11-23 | 北京福元医药股份有限公司 | 一种Brexpiprazole盐酸盐的纯化方法 |
| WO2017106641A1 (en) | 2015-12-17 | 2017-06-22 | Assia Chemical Industries Ltd. | Solid state forms of brexpiprazole |
| US10464931B2 (en) | 2015-12-28 | 2019-11-05 | Honour (R&D) | Process for the preparation of Quinolin-2(1H)-one derivatives |
| JP2019059672A (ja) * | 2015-12-28 | 2019-04-18 | 大日本住友製薬株式会社 | 治療抵抗性うつ病等の治療薬 |
| US10501450B2 (en) | 2016-02-01 | 2019-12-10 | Hexal Ag | Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations |
| US20170320862A1 (en) | 2016-05-03 | 2017-11-09 | Cadila Healthcare Limited | Process for the preparation of brexpiprazole and intermediates thereof |
| CN107365305A (zh) * | 2016-05-12 | 2017-11-21 | 上海奥博生物医药技术有限公司 | 一种依匹哌唑新晶型及其制备方法 |
| WO2017208251A1 (en) * | 2016-05-31 | 2017-12-07 | Cipla Limited | A new stable polymorph of brexpiprazole and process for preparation thereof |
| CN106188023A (zh) * | 2016-07-04 | 2016-12-07 | 山东川成医药股份有限公司 | 一种依匹唑派的精制方法 |
| PL233778B1 (pl) | 2016-07-19 | 2019-11-29 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu |
| WO2018033484A1 (en) | 2016-08-16 | 2018-02-22 | Hexal Aktiengesellschaft | Pharmaceutical compositions of a benzothiophene compound |
| US11123300B2 (en) | 2016-08-16 | 2021-09-21 | Hexal Ag | Immediate release tablet of a benzothiophene compound |
| CN107936005A (zh) * | 2016-10-13 | 2018-04-20 | 上海科胜药物研发有限公司 | 一种依匹哌唑新晶型ii及其制备方法 |
| CN111233848A (zh) * | 2016-12-14 | 2020-06-05 | 上海博志研新药物技术有限公司 | 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用 |
| US11072605B2 (en) | 2017-02-02 | 2021-07-27 | Hexal Ag | Crystalline brexpiprazole |
| EP3501506B1 (en) | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
| CN111440158A (zh) * | 2020-03-24 | 2020-07-24 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸依匹哌唑新晶型及其制备方法 |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| WO2022176017A1 (ja) * | 2021-02-16 | 2022-08-25 | 大塚製薬株式会社 | 非晶質体及び当該非晶質体を含む組成物 |
| WO2023067664A1 (ja) * | 2021-10-18 | 2023-04-27 | 大塚製薬株式会社 | ベンゾチオフェン化合物の新規結晶形及びその製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| MXPA06004489A (es) † | 2003-10-23 | 2006-06-20 | Otsuka Pharma Co Ltd | Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada. |
| EP1797039A1 (en) | 2004-09-13 | 2007-06-20 | Matrix Laboratories Ltd | Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| PE20090387A1 (es) * | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| JP2011500090A (ja) * | 2007-10-26 | 2011-01-06 | レプリジェン コーポレイション | 神経障害に役立つヒストンデアセチラーゼ・インヒビターを確認する方法 |
| PT2247282E (pt) * | 2008-01-30 | 2014-11-11 | Novartis Ag | Formulação de libertação controlada compreendendo octreotido e três polímeros lineares de polilactido-coglicolido |
| EP2233471A1 (en) * | 2009-02-06 | 2010-09-29 | Adamed Sp. z o.o. | A salt of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-quinolinone with 5-sulfosalicylic acid and its preparation process |
| AR082494A1 (es) † | 2010-08-24 | 2012-12-12 | Otsuka Pharma Co Ltd | Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona |
| EP3156056B1 (en) * | 2011-03-18 | 2023-12-06 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
| JP2012232958A (ja) * | 2011-05-09 | 2012-11-29 | Otsuka Pharmaceut Co Ltd | 注射製剤 |
| KR101911121B1 (ko) * | 2011-07-28 | 2018-10-23 | 오쓰까 세이야꾸 가부시키가이샤 | 벤조［ｂ］티오펜 화합물의 제조 방법 |
| JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
-
2013
- 2013-04-19 TW TW102114005A patent/TWI562991B/zh active
- 2013-04-22 AR ARP130101319A patent/AR090774A1/es unknown
- 2013-04-23 LT LTEP13722129.7T patent/LT2841431T/lt unknown
- 2013-04-23 NZ NZ630260A patent/NZ630260A/en unknown
- 2013-04-23 KR KR1020147032745A patent/KR102160395B1/ko active Active
- 2013-04-23 EP EP13722129.7A patent/EP2841431B2/en active Active
- 2013-04-23 US US14/396,224 patent/US9499525B2/en active Active
- 2013-04-23 PL PL13722129.7T patent/PL2841431T5/pl unknown
- 2013-04-23 HR HRP20170242TT patent/HRP20170242T4/hr unknown
- 2013-04-23 BR BR112014026424-4A patent/BR112014026424B1/pt active IP Right Grant
- 2013-04-23 SM SM20170130T patent/SMT201700130T1/it unknown
- 2013-04-23 WO PCT/JP2013/062681 patent/WO2013162046A1/en not_active Ceased
- 2013-04-23 CN CN201380021622.6A patent/CN104254530B/zh active Active
- 2013-04-23 EA EA201491933A patent/EA026541B1/ru not_active IP Right Cessation
- 2013-04-23 DK DK13722129.7T patent/DK2841431T4/da active
- 2013-04-23 ME MEP-2017-56A patent/ME02619B/me unknown
- 2013-04-23 RS RS20170214A patent/RS55742B2/sr unknown
- 2013-04-23 SG SG11201406790VA patent/SG11201406790VA/en unknown
- 2013-04-23 MX MX2014012527A patent/MX361723B/es active IP Right Grant
- 2013-04-23 IN IN8867DEN2014 patent/IN2014DN08867A/en unknown
- 2013-04-23 CA CA2870000A patent/CA2870000C/en active Active
- 2013-04-23 PT PT137221297T patent/PT2841431T/pt unknown
- 2013-04-23 MY MYPI2014703139A patent/MY170220A/en unknown
- 2013-04-23 JO JOP/2013/0114A patent/JO3325B1/ar active
- 2013-04-23 UA UAA201412555A patent/UA117456C2/uk unknown
- 2013-04-23 FI FIEP13722129.7T patent/FI2841431T4/fi active
- 2013-04-23 SI SI201330538T patent/SI2841431T2/sl unknown
- 2013-04-23 AU AU2013253372A patent/AU2013253372B2/en active Active
- 2013-04-23 ES ES13722129T patent/ES2617881T5/es active Active
- 2013-04-23 HU HUE13722129A patent/HUE031997T2/en unknown
- 2013-04-23 JP JP2014550214A patent/JP5952917B2/ja active Active
-
2014
- 2014-10-07 IL IL235044A patent/IL235044B/en active IP Right Grant
- 2014-10-14 CO CO14226629A patent/CO7111315A2/es unknown
- 2014-10-15 ZA ZA2014/07477A patent/ZA201407477B/en unknown
- 2014-10-17 PH PH12014502324A patent/PH12014502324A1/en unknown
-
2016
- 2016-10-14 US US15/294,644 patent/US10407415B2/en active Active
-
2017
- 2017-02-28 SM SM201700130T patent/SMT201700130B/it unknown
- 2017-03-07 CY CY20171100293T patent/CY1119103T1/el unknown
-
2019
- 2019-09-09 US US16/564,972 patent/US20200140424A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/985,177 patent/US20210115030A1/en not_active Abandoned
-
2022
- 2022-02-14 US US17/651,042 patent/US20230049327A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630260A (en) | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same | |
| PH12019502269A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
| NZ600008A (en) | Multicyclic compounds and methods of use thereof | |
| RU2011120816A (ru) | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов | |
| HRP20180098T1 (hr) | Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja | |
| JP2014526435A5 (OSRAM) | ||
| CY1114329T1 (el) | Νεοι προσδετες υποδοχεων αδενοσινης και χρησεις εξ' αυτων | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| JP2015514677A5 (OSRAM) | ||
| DOP2011000135A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
| MY160075A (en) | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| MX2012010658A (es) | Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa. | |
| EA201171172A1 (ru) | Применение в терапии производных хиназолиндиона | |
| EA201590406A1 (ru) | Мочевинные и амидные производные аминоалкилпиперазинов и их применение | |
| NZ630281A (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor | |
| AR077858A1 (es) | Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso | |
| MY196998A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| CL2007002768A1 (es) | Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki | |
| MX2014006015A (es) | Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1. | |
| MX2016001080A (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. | |
| WO2014057439A3 (en) | Compositions and methods for treatment of neurological diseases and its associated complications | |
| Suleymanov et al. | Variant of auto-allopsychic depersonalization in patients with latent schizophrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2018 BY CPA GLOBAL Effective date: 20170324 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2019 BY CPA GLOBAL Effective date: 20180309 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2021 BY CPA GLOBAL Effective date: 20200312 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2022 BY CPA GLOBAL Effective date: 20210312 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2023 BY CPA GLOBAL Effective date: 20220310 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2024 BY CPA GLOBAL Effective date: 20230309 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240307 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250307 |